Invention Grant
- Patent Title: Nucleic acid linked to a trivalent glycoconjugate
-
Application No.: US16091503Application Date: 2017-04-05
-
Publication No.: US10913945B2Publication Date: 2021-02-09
- Inventor: Christian Frauendorf , Mark Cameron
- Applicant: Silence Therapeutics GmbH
- Applicant Address: DE Berlin
- Assignee: Silence Therapeutics GmbH
- Current Assignee: Silence Therapeutics GmbH
- Current Assignee Address: DE Berlin
- Agency: Marshall, Gerstein & Borun LLP
- Priority: EP16163939 20160405
- International Application: PCT/EP2017/058112 WO 20170405
- International Announcement: WO2017/174657 WO 20171012
- Main IPC: A61K47/54
- IPC: A61K47/54 ; A61K31/7125 ; A61K47/56 ; C12N15/113
Abstract:
The present invention relates to a compound comprising a modified saccharide moiety conjugated to a nucleic acid. The compound is useful in medicine for RNA interference therapy or for research and diagnostic purposes. In particular, the compound is useful in treating liver disease.
Public/Granted literature
- US20190119676A1 NUCLEIC ACID LINKED TO A TRIVALENT GLYCOCONJUGATE Public/Granted day:2019-04-25
Information query
